利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.034 秒)

    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
    4.
    发明申请
    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof 有权
    可用作甲酰肽受体如1受体的配体的组合物及其使用方法

    公开(公告)号：US20060034863A1

    公开(公告)日：2006-02-16

    申请号：US11175003

    申请日：2005-07-05

    申请人： Thomas Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    发明人： Thomas Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    IPC分类号： A61K39/02 ,  A61K38/10

    CPC分类号： C07K14/523 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55522 ,  Y02A50/39 ,  Y02A50/401 ,  Y02A50/466 ,  Y02A50/484

    摘要： The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKβ8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKβ8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

    摘要翻译： 本发明人已经发现CKbeta8-1截短变体CKbeta8-1（25-116）是两种不同GPCR，趋化因子受体CCR1和甲酰肽受体1（FPRL1）的双功能配体。 因此，本发明人发现除了CCR1的功能活性外，CKbeta8-1（25-116）也是通过募集单核细胞和嗜中性粒细胞参与炎症反应和先天免疫的GPCR受体FPRL1的功能性配体。 此外，本发明人已经发现了称为SHAAGTIDE的CKbeta8-1的可变剪接外显子。 SHAAGTIDE与其母体趋化因子CKbeta8-1（25-116）一起在已知表达FPRL1的单核细胞和嗜中性粒细胞上完全起作用。 本申请一般涉及增强免疫应答。 这种免疫应答可以通过疫苗施用引起。 提供了诱导或增强对抗原的免疫应答的组合物和方法。 组合物和方法可用于治疗和预防用途（免疫）和产生抗体的疫苗制剂。

    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
    7.
    发明授权
    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof 有权
    可用作甲酰肽受体如1受体的配体的组合物及其使用方法

    公开(公告)号：US08637043B2

    公开(公告)日：2014-01-28

    申请号：US11175003

    申请日：2005-07-05

    申请人： Thomas J. Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    发明人： Thomas J. Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    IPC分类号： A61K39/02

    CPC分类号： C07K14/523 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55522 ,  Y02A50/39 ,  Y02A50/401 ,  Y02A50/466 ,  Y02A50/484

    摘要： The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKβ8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKβ8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1.This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

    摘要翻译： 本发明人已经发现CKbeta8-1截短变体CKbeta8-1（25-116）是两种不同GPCR，趋化因子受体CCR1和甲酰肽受体1（FPRL1）的双功能配体。 因此，本发明人发现除了CCR1的功能活性外，CKbeta8-1（25-116）也是通过募集单核细胞和嗜中性粒细胞参与炎症反应和先天免疫的GPCR受体FPRL1的功能性配体。 此外，本发明人已经发现了称为SHAAGTIDE的CKbeta8-1的可变剪接外显子。 SHAAGTIDE与其母体趋化因子CKbeta8-1（25-116）一起在已知表达FPRL1的单核细胞和嗜中性粒细胞上完全起作用。 本申请一般涉及增强免疫应答。 这种免疫应答可以通过疫苗施用引起。 提供了诱导或增强对抗原的免疫应答的组合物和方法。 组合物和方法可用于治疗和预防用途（免疫）和产生抗体的疫苗制剂。